Role of chromatin remodeling protein ARID1A in MLL-AF9 leukemogenesis
Evidence identifying ARID1A as a vital driver and therapeutic target in AML
(E) Kaplan-Meier estimation of real-world overall survival (rwOS) probability was performed for ARID1A_low and ARID1A_low patients. The index date is the date of diagnosis, and the entry date is the date of sequencing. Low ARID1A expression was significantly associated with improved rwOS (HR = 0.56; 95% CI: 0.39 - 0.81; p=0.002).
Lens Library
